Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.47)
# 845
Out of 5,180 analysts
47
Total ratings
51.28%
Success rate
5.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMNM Immunome | Maintains: Overweight | $33 → $30 | $19.30 | +55.44% | 4 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $95 → $100 | $79.48 | +25.82% | 4 | Mar 2, 2026 | |
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $78.72 | +20.68% | 1 | Dec 17, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $4.48 | +234.82% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $1.27 | +529.92% | 2 | Nov 24, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $10.18 | +47.35% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $8.89 | +102.47% | 4 | Nov 5, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $27.58 | +26.90% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.35 | +155.32% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $31.45 | +43.08% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $14.67 | +104.50% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $41.95 | +43.03% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $23.78 | +38.77% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $3.64 | +119.78% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $4.34 | +245.62% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.99 | +405.05% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $25.13 | +297.93% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.67 | +1,097.60% | 1 | May 14, 2024 |
Immunome
Mar 4, 2026
Maintains: Overweight
Price Target: $33 → $30
Current: $19.30
Upside: +55.44%
Kymera Therapeutics
Mar 2, 2026
Maintains: Overweight
Price Target: $95 → $100
Current: $79.48
Upside: +25.82%
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $78.72
Upside: +20.68%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $4.48
Upside: +234.82%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $1.27
Upside: +529.92%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $10.18
Upside: +47.35%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $8.89
Upside: +102.47%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $27.58
Upside: +26.90%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.35
Upside: +155.32%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $31.45
Upside: +43.08%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $14.67
Upside: +104.50%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $41.95
Upside: +43.03%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $23.78
Upside: +38.77%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.64
Upside: +119.78%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $4.34
Upside: +245.62%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.99
Upside: +405.05%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $25.13
Upside: +297.93%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.67
Upside: +1,097.60%